Overview

A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

Status:
Completed
Trial end date:
2021-04-27
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and efficacy of two anti-cancer drugs (gemcitabine and docetaxel) with and without the study drug known as olaratumab in participants with advanced soft tissue sarcoma (STS) or STS that has spread to another part(s) of the body.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Docetaxel
Gemcitabine
Olaratumab